Apricus Biosciences
6330 Nancy Ridge Drive
Suite 103
San Diego
California
92121
United States
Tel: 858-222-8041
Fax: 858-866-0482
Website: http://www.apricusbio.com/
381 articles about Apricus Biosciences
-
Ligand Partner Seelos Therapeutics Becomes a Public Company
1/25/2019
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Seelos Therapeutics, Inc. (NASDAQ: SEEL) announced that it has closed a reverse merger with Apricus Biosciences, Inc.
-
The CRL indicates that the FDA cannot approve the NDA for Vitaros in its present form.
-
Apricus Biosciences Provides Corporate Update and Third Quarter 2017 Financial Results
11/3/2017
Net loss for the quarter ended September 30, 2017 was $3.8 million, or loss per share of $0.29, compared to a net loss of $1.3 million, or loss per share of $0.19, for the third quarter of 2016.
-
Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call
10/26/2017
Company management will host a conference call to discuss financial results and other recent corporate highlights.
-
Apricus Biosciences Announces $3.7 Million Private Placement Priced At-The-Market
9/11/2017
-
Apricus Biosciences Announces FDA Acknowledgement Of Vitaros Class 2 NDA Resubmission
8/31/2017
-
Apricus Biosciences Files NDA Resubmission For Vitaros
8/29/2017
-
Apricus Biosciences Provides Corporate Update And Second Quarter 2017 Financial Results
8/3/2017
-
Apricus Biosciences Announces Corporate Update And Second Quarter 2017 Financial Results Conference Call
7/26/2017
-
Apricus Biosciences Provides Corporate Update And First Quarter 2017 Financial Results
5/12/2017
-
Apricus Biosciences Announces The Initiation Of Vitaros Drug-Device Human Factors Study
5/4/2017
-
Apricus Biosciences Announces Corporate Update And First Quarter 2017 Financial Results Conference Call
5/4/2017
-
Apricus Biosciences Regains Compliance With Nasdaq Continued Listing Requirements
5/3/2017
-
Apricus Biosciences Announces Pricing of $7 Million Public Offering
4/21/2017
-
Apricus Biosciences Announces Corporate Update, Fourth Quarter And Full Year 2016 Financial Results Conference Call
3/9/2017
-
Apricus Biosciences Receives Positive Nasdaq Listing Determination
2/9/2017
-
Apricus Biosciences Release: Biotech Announces Approval Of Vitaros For The Treatment Of Erectile Dysfunction In Mexico
1/18/2017
-
Apricus Biosciences Announces The Launch Of Vitaros For The Treatment Of Erectile Dysfunction In Lebanon By Elis Pharmaceuticals Limited
12/27/2016
-
Apricus Biosciences Provides Update On Vitaros NDA Following Receipt Of FDA Feedback
11/18/2016
-
Apricus Biosciences Announces Corporate Update And Third Quarter 2016 Financial Results Conference Call
11/2/2016